Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDEAL-PCI Extended Registry
NCT02974777Phase 4Withdrawn
- Sponsor
- Klinik Favoriten
- Primary completion
- Jan 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of aspirin + P2Y12 antagonist in coronary arteriosclerosis (2 arms), sponsored by Klinik Favoriten. Primary endpoints: Stent Thrombosis at 1 year and Bleeding at 1 year. Status: withdrawn.
02
Drugs
aspirin + P2Y12 antagonist
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NCT02974777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02974777.